CHINA - 2024/07/27: In this photo illustration, Johnson & Johnson logo is displayed on a smartphone ... [+] with a laptop keyboard background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIf you are a Johnson & Johnson investor and have been enjoying the stock’s steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric an ...

Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross. This technical pattern occurs when a stock’s short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend. Chart created using Benzinga ProFor Johnson & Johnson, the stock’s 50-day simple moving average (SMA) of $155.36 has crossed above the 200-day SMA of $154.46, signaling strong upward momentum.Golden Cross: What It Means For Johnson & Johnson ...

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies  Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+SPRING HOUSE, Pa., Aug. 29, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biolog ...

In the past three months, J&J’s (JNJ) stock has risen 12.8% compared with an increase of 11.4% for the industry. J&J has also outperformed the sector as well as the S&P 500 in the same timeframe. J&J’s stock has also been trading above its 200-day and 50-day moving averages since mid-July.JNJ Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchMost of the stock’s outperformance was related to J&J’s strong second-quarter results, wherein it beat estimates for both earnings and ...

Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved its lung cancer drug Rybrevant (amivantamab) for expanded use.The EC approved a type II extension of indication for Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions after failure of prior therapy, including an EGFR tyrosine kinase inhibitor (TKI).JNJ's Stock PerformanceShares of JNJ have increa ...

IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on ... [+] October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesWe believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. T ...

Johnson & Johnson (JNJ) announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), harboring susceptible FGFR3 genetic alterations.The drug has been approved for UC patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.UC is the most common type of bladder cancer. Europe has the highest rate of b ...

These stocks have quality businesses behind them.Some investors might be feeling the brunt of stock market volatility as concerns about inflation persist. The last several years have been a bumpy ride, that's for certain.If you're focused on the long term, you should be holding stocks of great companies that can weather the storm. You should hang on to them for several years at minimum but more likely a decade or more. And if you're only putting your cash into quality companies that you're comfortable with ...

Nudphon Phuengsuwan Introduction I started covering Johnson & Johnson (NYSE:JNJ) in September of last year, when the stock became interesting again, as spin-off and lawsuit headlines provided several buyable corrections. As we can see below, I have written about this company three times. All of my calls are profitable - yet not by a lot. My most recent article was published on March 28, when I focused on its transition to high-growth healthcare markets. Since then, shares have returned 3.5%, lagging the 6% ...

patpitchaya/iStock via Getty Images JNJ stock: buy rating reiterated It was about three months ago that I last analyzed Johnson & Johnson (NYSE:JNJ) stock. As the following screenshot shows, my last article was titled "Johnson & Johnson: Market Will Regret The Overreaction" and rated the stock as a buy. The article argued that recent price corrections were an overreaction to the temporary issues the stock has been facing such as the talc-related bankruptcy filings and the Stelara patent expiration. Quote: T ...